

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Randy K. BLEDSOE et al.

Serial No.: 10/600,751 Filing Date: June 20, 2003 Art Unit: 1645

Examiner:

For:

Structure of a Glucocorticoid Receptor Ligand Binding Domain Comprising an Expanded Binding Pocket and Methods Employing Same

**Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[X] [ ]	Copies of the references are enclosed Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.						
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing						
		of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).						
В.,	[]	The Information Disclosure Statement transmitted herewith is being filed <b>after</b> three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but <b>before</b> the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first.						

## **CERTIFICATE OF MAILING (37 CFR 1.8)**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

## Atty. Docket No. PU4803US

	IJ	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.								
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).								
C.	[]	The Information Disclosure Statement transmitted herewith is being filed <b>after</b> a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.								
	In accordance with the requirements of 37 CFR 1.97(d):									
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]								
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and								
	[]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.								
[X]		charge any required fees to Deposit Account No.07-1392. cate copy of this paper is attached.								

Respectfully Submitted,

Attorney of Record: Virginia C. Bennett

Registration No. 37,092

Date: 12 Mar 04

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1012 Facsimile: (919) 483-7988

FORM PTO	<b>2</b> 449	NSCLOSURE ST	ATEMENT		ATTORNEY DOCKET NO.		SERIAL NO.			
ONWA	LIOIN	NSCLOSURE ST	AIEWENI	PU4803US APPLICANT		10/600,751				
/ 🖰		<u>e7</u> ]			Randy K. BLEDSOE et al.					
MAR 1	7 2004	<u> </u>			FILING DATE GROUP					
		<b>E</b> /			June 20, 2003 1645					
U.S. PATENT DOCUMENTS Filing										
1	19 0	_						Filing Date		
Examiner Initials		Patent	Issue Date		Name	Class	Subclass	If Appropriate		
Illitials		Number			·	<u> </u>		77.15		
						ļ				
				ļ		<u> </u>				
				<u> </u>			<del> </del>			
			• ·			<del> </del>				
				<u> </u>				<del></del>		
	l	<u> </u>	L	Iontinue on p	2206		1	<u> </u>		
					T DOCUMENTS					
	l	Document	Publication	1	- DOCCINDINIO	Γ	1	Translation		
		Number	Date		Country	Class	Subclass	Yes   No		
				,	•			1		
					_	ļ				
				<u> </u>		<u> </u>	_1	<u> </u>		
		OTHED DOCUM		ontinue on p	oage Title, Journal-Date, P	aga Numb	or Fto)			
	1.				orticoid receptor ligand			novel mode		
	1.				nition," Cell 110(1):93			iover mode		
	2.				he heteromeric structur			s." Annal.		
		NY Acad. Sci. 746						,		
	3.				pecificity in the binding			rogen		
					y <b>275(34)</b> :26164-26171					
	4.				operties of recombinant			outative role		
					hem. Molec. Biol. 37(4)					
	5.				sp90 and hsc70 are both The Journal of Biologic					
		(Jul. 2000).	by gracocorricon	u receptor,	The Journal of Biologic	cai Chemis	11 y 213(29).223	97-22004		
	6.									
					onist dihydrotestosteron					
		<b>98(9)</b> :4904-4909		ŭ	•	•				
	7.	Williams et al., "A	Atomic structure	of progester	rone complexed with its	receptor,"	Nature 393(668	3):392-296		
(May 1998).										
	8. Xu et al., "Binding of hsp90 to the glucocorticoid receptor requires a specific 7-amino acid sequence at the									
amino terminus of the hormone-binding domain," The Journal of Biological Chemistry 273(22):13918-13										
	l	(May 1998).	-							
EXAMINER		<del></del>		Continue on	page	I DATE O	ONCIDERED			
EARMINER					DATEC	ONSIDERED				
EXAMINER	: Initia	Lif citation conside	ered whether or r	not citation	is in conformance with	MPEP 8 60	9. Draw line the	rough		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through										